Subtype
Endocrine Carcinoma
CI-CAN-00000838Explore in graph →
575 active trials16 approved drugs58 evidence items
- NCIt
- C215715
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000838Explore in graph →
Clinical trials
1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (236)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06663098 | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).(CARRY-ON) | recruiting | Phase 2 | 142 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 |
| clinicaltrials |
| NCT06869239 | Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy | recruiting | — | 65 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06853678 | Second-line Immunotherapy for ES-SCLC | recruiting | N/A | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06242119 | Clinical Application of the J-PET Scanner Prototype(JPET2Clinic) | recruiting | — | 25 | Jagiellonian UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients(CRISP) | recruiting | — | 12,400 | AIO-Studien-gGmbHOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06733740 | Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma | recruiting | — | 3,000 | Chinese PLA General HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06613009 | Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 1 | 190 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Feb 11, 2025 | clinicaltrials |
| NCT06800482 | A Study of Online Follow-up in Patients With Papillary Thyroid Cancer | recruiting | N/A | 388 | West China HospitalOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06791005 | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | recruiting | Phase 3 | 400 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06645951 | Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma | recruiting | — | 300 | F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo SettoreOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06780826 | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | recruiting | — | 1,430 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06769971 | Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC | recruiting | Phase 2 | 80 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06480864 | Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer | recruiting | N/A | 38 | Yunpeng LiuOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06725576 | Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma | recruiting | — | 201 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06749691 | Liposomal Irinotecan and Apatinib in ES-SCLC(LIAES) | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06440057 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. | recruiting | Phase 1 / Phase 2 | 78 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05668962 | Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | recruiting | Phase 3 | 180 | Luye Pharma Group Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06727370 | Cognitive Screening in Lung Cancer Patients | recruiting | — | 200 | European Institute of OncologyOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT05945745 | Molecular Analysis and Treatment Options of SCLC | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06698965 | Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05424692 | Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer | recruiting | N/A | 200 | Peking Union Medical College HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06498479 | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05766098 | Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY(PTC-ARRAY) | recruiting | — | 600 | Istituto Auxologico ItalianoOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT05797415 | Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers(BLS) | recruiting | — | 25 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06592755 | Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC | recruiting | — | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06247163 | PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.(PET-ART) | recruiting | — | 30 | University Hospital, EssenOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04951947 | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer | recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06527898 | Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06562920 | Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer(Neoadjuvant) | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06393816 | FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum(FIRST-NEC) | recruiting | Phase 2 | 80 | Centre Leon BerardOTHER | 2 | Aug 2, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05913427 | Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)(PESETA) | recruiting | Phase 2 | 80 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | recruiting | — | 750 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06514118 | Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer | recruiting | — | 70 | Qingdao Central HospitalOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06295926 | Serplulimab Combined With CCRT for LS-SCLC. | recruiting | Phase 2 | 96 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06485544 | Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial | recruiting | Phase 2 | 104 | Tang-Du HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06475209 | Adebrelimab + Apatinib in SCLC Maintenance Therapy | recruiting | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06467786 | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | recruiting | Phase 4 | 24 | Tang-Du HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06110572 | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation(TESSERACT) | recruiting | Phase 1 / Phase 2 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06464068 | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA(DURVASCC) | recruiting | Phase 2 | 66 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06371482 | Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) | recruiting | Phase 2 | 58 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06256237 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial | recruiting | Phase 2 | 30 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06418087 | Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)(DUPLE) | recruiting | Phase 2 | 49 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06369181 | Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC | recruiting | — | 50 | Fudan UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06223711 | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | recruiting | Phase 2 | 43 | Universität des SaarlandesOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06333587 | Minimally Invasive Treatments of the Thyroid(MIPA-MITT) | recruiting | — | 270 | European Institute of OncologyOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | recruiting | Phase 3 | 686 | Luye Pharma Group Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06286631 | Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale | recruiting | — | 800 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2025source: clinicaltrials